Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Pharm Biotechnol. 2012 Jun;13(8):1409-17.

Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair.

Author information

1
Neurology Service, William S. Middleton Memorial Veterans Hospital, University of Wisconsin, Madison, WI, USA. carrithers@neurology.wisc.edu

Abstract

Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and can cause severe neurological disability. Current immune therapy with beta-interferons, glatiramer acetate, immune suppressives, or selective adhesion molecule inhibitors can reduce the frequency and severity of acute attacks in a majority of patients but have little effect on the progressive phase of the disease. Patients who require aggressive immune therapy are also at risk for the development of potentially fatal opportunistic infections. Here current and emerging immune therapy options are discussed, and immune-mediated strategies to preserve normal immune surveillance and mediate tissue repair are proposed.

PMID:
22339217
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center